OLIGONUCLEOTIDE THERAPEUTICS SOCIE… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2002

Legal Domicile

Principal Officer

REBECCA MILES

Phone

6198076541

Tax Period

2025-01-01 to 2025-12-31

OLIGONUCLEOTIDE THERAPEUTICS SOCIETY, founded in 2002, is a community nonprofit in the Medical Research sector that reported $1.7M in total revenue in fiscal year 2025. Expenses of $1.5M left a modest 13% surplus.

Mission

OTS is an educational organization that brings together scientists from around the world to share research and foster collaborations in an effort to further the development of oligonucleotide therapeutic drug development.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $5,635

Program Service Revenue $1,654,152

Investment Income $31,242

Other Revenue $1,650

TOTAL REVENUE $1,692,679

Expense Breakdown

Grants Paid $113,122

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $1,409,460

Other Expenses $1,363,336

TOTAL EXPENSES $1,476,458

Year-over-Year Comparison

	2025	2024	Change
Revenue	$1,692,679	$1,653,140	+0.0%
Expenses	$1,476,458	$1,324,007	+0.1%
Net Income	$216,221	$329,133	-0.3%

Key Indicators

✗ Grants to Organizations ✓ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
RICHARD GEARY	PAST PRESIDENT	1.00	Officer Director	$0	$0	$0
REBECCA MILES	President	1.00	Officer Director	$0	$0	$0
ANNABELLE BISCANS	Director	1.00	Officer Director	$0	$0	$0
JULIA ALTERMAN	Director	1.00	Director	$0	$0	$0
MASAD J DAMHA	HONORARY MEMBER	1.00	Director	$0	$0	$0
HASSAN FAKIH	Director	1.00	Director	$0	$0	$0
ALEX GARANTO	Secretary	1.00	Officer Director	$0	$0	$0
BRUNO GODINHO	Director	1.00	Director	$0	$0	$0
ARELIE GOYENVALLE	Director	1.00	Director	$0	$0	$0
MAJA JANAS DE ANGELIS	Treasurer	1.00	Officer Director	$0	$0	$0
ANASTASIA KHVOROVA	Director	1.00	Director	$0	$0	$0
MARIE WIKSTROM LINDHOLM	Director	1.00	Director	$0	$0	$0
TIMOTHY YU	Director	1.00	Director	$0	$0	$0
KRYSTAL JOHNSON	Director	1.00	Director	$0	$0	$0
FRITZ ECKSTEIN	HONORARY MEMBER	1.00	Director	$0	$0	$0
MIKE GAIT	HONORARY MEMBER	1.00	Director	$0	$0	$0
MANO MANOHARAN	HONORARY MEMBER	1.00	Director	$0	$0	$0
JOHN ROSSI	HONORARY MEMBER	1.00	Director	$0	$0	$0
LAURA SEPP-LORENZINO	PRESIDENT ELECT	1.00	Officer Director	$0	$0	$0
ANNEMIEKE AARTSMA-RUS	Director	1.00	Director	$0	$0	$0
HELENE TRAN	Director	1.00	Director	$0	$0	$0
JONATHAN K WATTS	Director	1.00	Director	$0	$0	$0
SARAH ALLEN	TRAINEE REP	1.00	Director	$0	$0	$0
ILARIA BRENTARI	TRAINEE REP	1.00	Director	$0	$0	$0
DANIEL KNIGHT	TRAINEE REP	1.00	Director	$0	$0	$0
EMILIO HARRIS-MOSTERT	TRAINEE REP	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$1,692,679	$1,476,458	$2,280,174	$216,221
2024	$1,653,140	$1,324,007	$2,063,953	$329,133
2023	$1,561,718	$1,644,646	$1,734,820	$-82,928
2022	$1,230,167	$1,077,810	$1,817,748	$152,357
2021	$788,991	$388,431	$1,697,866	$400,560
2020	$601,451	$313,631	$1,260,770	$287,820
2019	$844,284	$830,066	$977,950	$14,218
2018	$822,106	$667,627	$963,733	$154,479

OLIGONUCLEOTIDE THERAPEUTICS SOCIETY